期刊
CHEMICAL COMMUNICATIONS
卷 57, 期 3, 页码 367-370出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0cc03399e
关键词
-
The study presented a novel immunosensor for the quantitative and selective detection of ADAs against a drug, which may enhance the effectiveness of clinical treatment.
The efficacy of immunotherapy can be undermined by the development of an immune response against a drug/antibody mediated by anti-drug antibodies (ADAs) in treated patients. We present the first label-free EGOFET immunosensor that integrates a biological drug, Nivolumab (Opdivo (c)), as a specific recognition moiety to quantitatively and selectively detect ADAs against the drug. The limit of detection is 100 fM. This demonstration is a prelude to the detection of ADAs in a clinical setting in the treatment of different pathologies, and it also enables rapid screening of biological drugs for immunogenicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据